DIJON, France – (COMMERCIAL THREAD) – Regulatory news:
ONCODESIGN (FR0011766229 – ALONC) (Paris: ALONC), a biopharmaceutical group specializing in precision medicine, today announces a strategic collaboration agreement with Covalab, specialist in the development and production of tailor-made antibodies with a unique library of nanobodies, CheMatech, European leader in the design, synthesis and supply of chelating agents, and ABX-CRO, specializing in the preclinical and clinical development of radiopharmaceuticals in oncology.
The combination of these areas of expertise led to the launch of the DRIVE-MRT ™ (Molecular Radiotherapy) offer integrating the whole Drug Discovery process specialized in targeted systemic radiotherapy (Theranostics) from the generation of radiolabeled biological vectors, the optimization of leads and the generation of preclinical drug candidates to the granting of the IND and the design and conduct of radiopharmaceutical clinical studies.
the DRIVE-MRT solution allows the rationalization, design and optimization targeted and effective radiopharmaceuticals against certain metastatic cancers.
Since Lutathera, indicated for treatment of inoperable or metastatic gastroenteropancreatic neuroendocrine tumors with positive somatostatin receptors (GEP-NET), until recent results ASCO this year concerning the substantial increase in survival observed for internal radiotherapy vectored by PSMA-ligand labeled with 177Lu in patients with high-grade metastatic castration-resistant prostate cancer (CRPC), targeted vector radiotherapy is now attracting many players in the pharmaceutical industry as good as clinicians while searching effective treatments for metastatic disease. According to a recent study1, the global market for vectorized radiotherapeutic products is expected to grow by around 40% between 2019 and 2025, reaching an estimate $ 8.0 billion in 2025.
Philippe Genne, Chairman and CEO and founder of Oncodesign, declares: “As part of our approach to developing the drug discovery services market and like our first DRIVE-SM offer, specific to small chemical molecules, we are at this precise moment showing ourselves a champion in this new emerging market segment. on which we can count on more than a decade of experience in radiopharmaceuticals acquired in particular with radiotracers and PharmImage. We are pleased to join forces with these leading partners to offer this new service offering, a drug discovery engine for translational research, from preclinical to clinical, serving the many customers in the radiopharmaceutical sector. Historically, Oncodesign has provided innovative drug discovery programs on behalf of third party clients – this partnership marks a new chapter for our DRIVE offering and for the radiopharmaceutical industry.”.
Fabrice Viviani, Managing Director and Head of the Oncodesign Service Business Unit, adds: “We are delighted to partner with Covalab, CheMatech and ABX-CRO, recognized major players in the discovery and design of new innovative drugs for precision medicine. It is by combining our strengths and our areas of expertise that we are now able to offer the unique and fully integrated DRIVE-MRT offer covering the discovery of the target, the generation of radiopharmaceutical vectors and their clinical development in oncology.”.
Oncodesign is a biopharmaceutical company dedicated to precision medicine, founded in 1995 by its current CEO and majority shareholder, and listed on the Euronext Growth Market since April 2014. Its mission is to discover effective therapies to fight cancer and others. diseases without therapeutic solutions. . Thanks to its unique experience acquired by working with more than 1000 clients, including the world’s largest pharmaceutical companies, and its unique technological platform combining Artificial Intelligence, advanced medicinal chemistry, pharmacology, regulated bioanalysis, medical imaging, Oncodesign is able to select new therapeutic targets, to design and develop potential preclinical candidates up to clinical phases. Oncodesign has configured its organization to offer innovative services to its customers and license its proprietary molecules. Applied to kinase inhibitors, which represent a market estimated at more than 65 billion dollars by 2027 and representing nearly 25% of the R&D expenditure of the pharmaceutical industry, Oncodesign’s technology has already made it possible to target several molecules. promising companies with strong therapeutic potential, in oncology and elsewhere, as well as partnerships with global pharmaceutical groups. Oncodesign is based in Dijon, France, at the heart of the city’s university and hospital hub, and within the Paris-Saclay hub. Oncodesign has 230 employees in 3 Business Units (BU): Service, Biotech, Artificial Intelligence and subsidiaries in Canada and the USA. www.oncodesign.com
This press release contains certain forward-looking statements and estimates concerning the financial condition, results of operations, strategy, plans and future performance of the Company and the markets in which it operates. These forward-looking statements and estimates may be identified by words such as “anticipate”, “believe”, “may”, “could”, “estimate”, “expect”, “intend”, “is designed to “,” May, “” could “,” plan “,” potential “,” predict “,” objective “,” should “, or the negative of these expressions and the like. They incorporate all matters that are not facts Forward-looking statements, forecasts and estimates are based on management’s current assumptions and on the assessment of risks, uncertainties and other factors, known and unknown, which were considered reasonable at the time they were made, but which may prove to be incorrect. Events and results are difficult to predict and depend on factors beyond the control of the Company. Consequently, the actual results, financial condition, performance and / or achievements of the Company or industry can be be materially different from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Due to these uncertainties, no representation is made as to the accuracy or fairness of these forward-looking statements, forecasts and estimates. In addition, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and the Company assumes no obligation to update or revise any of them, whether whether as a result of new information, future events or otherwise, except as required by law.